Advertisement

Up-regulation of interleukin-33 serum levels in metastatic prostate cancer

American Journal of BioMedicine  Volume 2, Issue 8, pages 928-939, August 2014


Xiaoli Zheng; Jin Chu; Hong Jing; Le Choi; Min Wang; Wei Zhou

Abstract

Prostate cancer is one of the most frequent cancers worldwide. IL-33 is the most recently described member of the IL-1 family of cytokines and is a ligand for the ST2 receptor. IL-33 is expressed intracellularly predominantly by stromal cells such as endothelial and epithelial cells as well as smooth muscle cells and fibroblasts and it is involved in the pathogenesis of different inflammatory process. The present study was undertaken to evaluate the prognostic significance of the serum levels IL-33 in patients with prostate cancer Ninety-five patients with prostate cancer, ages 59–88 years (71.2 ± 0.34 years), were examined in the present study, the exclusion criteria were presence of autoimmune diseases and none were under any treatment for prostate cancer at the time of examination. The diagnosis of prostate cancer was confirmed by needle biopsy or by C. Blood for the measurement of serum IL-33 was collected into nonheparinized tubes. Prognostic significance of tumor on disease-specific survival was assessed using univariate and multivariate Cox’s proportional hazards model analyses. Serum IL-33 levels were significantly higher in patients with metastatic prostate cancer than in patients with stage B and stage C prostate cancer, and univariate analysis demonstrated that IL-33 was associated with a poor prognosis in metastatic prostate cancer patients. These results indicate that the serum IL-33 level may be associated with the prognosis of patients with prostate cancer.

Keywords: IL-33; Prostate cancer; Autoimmune diseases; Univariate and multivariate Cox’s proportional hazards model analyses


  Limited Access               HTML                 Full Text-PDF                Feedback


References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10–29. [PubMed]

2. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer 2008; 113: 1097–1106. [PubMed]

3. Rashid MH,Chaudhary UB. Intermittent androgen deprivation therapy for prostate cancer. Oncologist 2004; 9: 295–301. [PubMed]

4. Pomerantz M,Kantoff P. Advances in the treatment of prostate cancer. Annu Rev Med 2007; 58: 205–220. [PubMed]

5. Bolla M,Collette L,Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–106. [PubMed]

6. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, Pfaffenberger S, et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 2013; 60:16–26. [Abstract/FREE Full Text]

7. Cohen EH, Robinson J, Margolis P, Gaut M, Alperson A, Feagin M. Prostate brachytherapy: the impact of smoking on recurrence and overall survival of localized prostate cancer. American Journal of BioMedicine  2013;1(2): 58-72. [Abstract/FREE Full Text]

8. Schmitz J, Owyang A, E Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479–490. [Abstract/FREE Full Text]

9. Qiu Y., Robinson D., Pretlow T. G., Kung H. J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA 1988; 95: 3644-3649. [Abstract/FREE Full Text]

10. L. Pastorelli, R.R. Garg, S.B. Hoang, L. Spina, B. Mattioli, M. Scarpa, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci USA 2010;107: 8017–8022. [Abstract/FREE Full Text]

11. Cominelli F. Cytokine-based therapies for Crohn’s disease—new paradigms. N Engl J Med 2004; 351: 2045–2048. [Abstract/FREE Full Text]

12. Yousif NG, Alhasani S, Slimani H, Doug J, Mohammad BI, Machil S, et al. The role of IL-23 in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling. In Journal Of Clinical Oncology 2014; 32: 4. [Google Scholar]

13. Yanaba K, Yoshizaki A, Asano T, Kadono T,  Sato T. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol 2011; 30: 825–830. [Abstract/FREE Full Text]

14. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA. For the Zoladex Study Group. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. J. Am. Med. Assoc 1991; 265: 618-621. [Abstract/FREE Full Text]

15. Conti G, La Torre G, Cicalese V, Micheletti G, Ludovico MG, et al. Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 2008; 80: 59–64. [PubMed]

16. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009; 101: 878–887. [PubMed]

17. Ryan CJ, Elkin EP, Cowan J, Carroll PR. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer 2007;110: 81–86. [PubMed]

18. Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, et al. Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden. Eur J Cancer 2012; 48: 1672–1681. [PubMed]

19. Van Hemelrijck M, Adolfsson J, Garmo H, Bill-Axelson A, Bratt O, et al. Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe. Lancet Oncology 2010; 11: 450–458. [PubMed]

20. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, et al. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol 2011; 185: 833–839. [PubMed]

21. Lund L, Borre M, Jacobsen J, Sørensen HT, Nørgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study. Urology 2008; 72(6): 1258-62. [PubMed]

22. Grönberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer 1996;77(1):138-43. [PubMed]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: